Health care utilization and HIV clinical outcomes following Affordable Care Act implementation in California: A longitudinal study

CURRENT STATUS: UNDER REVIEW

BMC Health Services Research  BMC Series

Derek D. Satre
derek.satre@ucsf.eduCorresponding Author
ORCiD: https://orcid.org/0000-0002-4228-1504

Sujaya Parthasarathy
Kaiser Permanente San Francisco Medical Center

Michael J. Silverberg
Kaiser Permanente Northern California

Michael Horberg
Mid-Atlantic Permanente Research Institute

Kelly C. Young-Wolff
Kaiser Permanente Northern California Division of Research

Emily C. Williams
University of Washington

Paul Volberding
Art Institute of California San Francisco Jamie A MacInnis Memorial Library

Cynthia I. Campbell
Kaiser Permanente Northern California, Division of Research

DOI: 10.21203/rs.3.rs-21308/v1

SUBJECT AREAS
Health Economics & Outcomes Research  Health Policy

KEYWORDS
health care reform, Affordable Care Act, AIDS Drug Assistance Program, insurance, mental health, HIV viral suppression, race/ethnicity
Abstract

Background: The Affordable Care Act (ACA) increased insurance coverage for people with HIV (PWH) in the United States, yet post-ACA health care utilization and HIV outcomes have rarely been examined.

Methods: Among PWH newly enrolled in an integrated health care system (Kaiser Permanente Northern California) in 2014 (N=880), we examined use of health care and modeled associations between enrollment mechanisms (enrolled in a Qualified Health Plan through the California Exchange vs. other sources), deductibles (none, $1-$999 and >= $1000), receipt of benefits from the California AIDS Drug Assistance Program (ADAP), demographic factors, and three-year patterns of health service utilization (primary care, psychiatry, substance treatment, emergency, inpatient) and HIV outcomes (CD4 counts, viral suppression).

Results: Health care use was greatest immediately after enrollment and decreased over three years. Those with high deductibles were less likely to use primary care (OR=0.64, 95% CI=0.49 - 0.83, p < 0.001) or psychiatry OR=0.58, 95% CI=0.36, 0.93, p=0.02) than those with low or no deductibles. Enrollment via the Exchange was associated with fewer psychiatry visits (rate ratio [RR]=0.38, 95% CI=0.17 - 0.83; p=0.02), but ADAP was positively associated with number of psychiatry visits (RR=2.22, 95% CI=1.22 – 4.05 p=0.01). There was no association between enrollment mechanism or deductibles and HIV outcomes, but ADAP enrollment was associated with viral suppression (OR=2.23, 95% CI=1.35 - 3.68, p<0.001). Non-white PWH were less likely to be virally suppressed, (OR=0.47, 95% CI= 0.31 - 0.71, p< 0.001).

Conclusions: In this sample of PWH drawn from an integrated health care system in California, findings suggest that enrollment via the Exchange and higher deductibles were negatively associated with some aspects of service utilization but did not impact HIV outcomes; support from ADAP appeared to help patients achieve viral suppression; ethnic disparities remain important to address in post-ACA health services for PWH even among those with access to insurance coverage.

Introduction

Major components of the Affordable Care Act (ACA) [1] were introduced in 2014 to increase access to
health insurance coverage in the U.S., particularly for vulnerable populations including people with HIV (PWH). It was expected that mandates of the ACA (e.g., establishment of state insurance exchanges, and inclusion of psychiatric and substance use treatment as essential benefits) implemented in 2014 would increase health care utilization and quality, leading to improved behavioral health and HIV clinical outcomes [2–4].

Early evaluations suggest that some of these expectations have been met. A large multi-state study by the HIV Research Network found a decrease in Ryan White / uncompensated care in Medicaid expansion states post-ACA and a small increase in private coverage in non-expansion states [5]. Among PWH enrolled in a California health care system after ACA implementation, more new enrollees with HIV also had a primary care visit within six months of enrollment in 2014 compared with a cohort that enrolled in 2012, and rates of HIV viral control improved [6]. Research in Virginia has found improvement in viral suppression following increased access to coverage through the ACA [7, 8]. Similarly, a study based on Nebraska found that insurance enrollment was independently associated with improved health outcomes including viral suppression [9].

However, little is known about the degree to which newly enrolled PWH maintain access to services within healthcare systems and what their HIV clinical outcomes are over time. In addition, specific facets of the ACA, such as enrollment via new state insurance exchanges and increased patient cost sharing via higher deductibles, have the potential to influence care. For example, a previous evaluation of PWH found that new enrollees post-ACA (2014) had more substance use disorders and were more likely to be enrolled in high-deductible plans compared to pre-ACA enrollees (2012) [6], indicating that newly enrolled PWH post-ACA may have greater behavioral healthcare needs as well as financial obstacles to accessing services.

It remains unknown to what extent enrollment through state insurance exchanges and higher deductibles influence outcomes. Exchanges provide access to tax credits, a range of coverage levels, HIV-specific guidance on planning care continuity, and information about medication benefits relevant to PWH that might not be easily accessible through other sources of coverage, e.g., through employers [10, 11], and thus could have a potentially positive impact on subsequent utilization and
outcomes. Deductibles may pose a barrier to accessing care, as studies in other populations have shown [12, 13].

The AIDS Drug Assistance Program (ADAP) continues to play a role in maintaining access to care, providing medications, premium and out-of-pocket financial assistance to low-income PWH [14, 15]. A prior study by McManus and colleagues [8] found that Virginia ADAP client enrollment in qualified health plans increased in 2015 compared with the prior year and varied based on demographic and health care delivery factors. Given the potential positive impact of ADAP on access to care even in an insured patient population, we included ADAP in our models along with enrollment via the Exchange and deductible level.

The current study investigated health care utilization and HIV control in a large health system, Kaiser Permanente Northern California (KPNC). This system has an integrated model that is becoming increasingly common [16, 17], and follows the standards for health services required of plans offered on the California Exchange [18]. We anticipated that utilization would be greatest immediately after enrollment, reflecting potential pent-up demand for care. We examined factors associated with utilization as conceptualized by the Andersen model of health care utilization [19, 20]. The model proposes that utilization is determined by predisposing (e.g., race/ethnicity and other demographic factors), need (e.g., HIV diagnoses) and enabling factors (e.g., benefit plan, enrollment through the Exchange) [21]. Controlling for demographic factors and ADAP participation, we expected that utilization would be higher and that HIV outcomes would be better among PWH with lower deductibles, and that enrollment via the Exchange also might have a positive effect on these outcomes.

Methods
Setting
KPNC is a large, integrated health care system with over 4 million members. Members receive coverage through employers, government programs (e.g., Medicaid and Medicare) and individual plans. KPNC offers comprehensive HIV care. Treatment is provided by HIV specialists integrated into primary care, with support provided by HIV specialty nurses, case managers, and clinical pharmacists.
Patients enrolled in ADAP can fill prescriptions directly through KPNC pharmacies. Psychiatry and substance use treatment are available to members [22], as well as emergency department (ED) and inpatient care.

**Study Sample And Data Source**
Participants were identified from the KPNC HIV registry, an up-to-date list of HIV-positive patients, clinical HIV data, and demographic characteristics. The registry is populated through active monitoring of electronic inpatient, outpatient, laboratory, and pharmacy databases for sentinel indicators of HIV infection. HIV-positivity is confirmed through medical record review. The registry has > 24,000 historical PWH, with 8,389 active patients during 2014.

Patients included in the present analysis were adults newly enrolled in KPNC between 1/1/2014–12/31/2014 (with no KPNC coverage recorded in the prior six months) and were confirmed HIV-positive within six months post-enrollment (N = 880). Linkage to other databases through medical record identifiers permits analysis of service utilization and HIV outcomes. Study procedures were approved by the University of California San Francisco (UCSF) and KPNC Institutional Review Boards and included waivers of informed consent.

**Measures**
We obtained patient characteristics and services use from the electronic health record (EHR), and HIV clinical outcomes data from the HIV registry. Demographic variables included sex, age, and race/ethnicity. Coverage mechanism included enrollment via the California Exchange vs. other mechanisms (e.g., employer-based large group purchasers or individual plans not purchased on the Exchange). KPNC pharmacy databases include codes that indicate whether the fill was subsidized by ADAP; enrollment was assessed from HIV prescription fills in 2014. Deductible limits were classified into 3 levels (none, $1-$999 and >= $1000), as in prior studies within KPNC [23, 24]. Since these may change over time, for analyses we used the values that were applicable at enrollment and every six months thereafter.

Utilization measures were aggregated in six-month intervals beginning from the post-intake date for up to 36 months (through 12/31/2017) yielding a maximum of six repeated measures. Total
outpatient visit count as well as type (primary care, psychiatry, specialty substance use treatment, ED, inpatient) were summarized for the six time periods.

For HIV clinical outcomes, we created an indicator variable for each six-month period for HIV RNA suppression, defined as HIV RNA levels < 75 copies/mL [25]; on the few occasions when an individual had more than one lab result per time-period, we used the most recent observation. We used continuous measures of CD4 counts for each six-month period, using mean CD4 count in case of multiple measures per six-month period.

Analyses
Over thirty-six months post-enrollment, we examined trends in service utilization including visits to primary care (which includes HIV services), psychiatry, substance use treatment, inpatient hospitalization and ED use; and HIV clinical outcomes using bivariate statistics. To account for correlation between repeated measures, we used generalized estimating equations methodology [26]. Using multivariable logistic regression, we examined whether deductible level, enrollment via the Exchange, ADAP and demographic characteristics were associated with use of health care and HIV outcomes in the three years post-enrollment.

We modeled psychiatry and specialty substance use clinic visit counts using the Poisson distribution since we had count data (number of days) with over dispersion of zeroes (no visits) and decreasing probability of having multiple visits. We used the software’s built-in capability to correct for over-dispersion (the dispersion parameter is estimated by the ratio of the deviance to its degrees of freedom). The parameter estimates are not affected but the estimated covariance matrix is inflated by this factor; this is the conventional approach in Poisson regression. We included member months as an offset term to account for varying exposure length (i.e., varying length of membership due to attrition). We used the negative binomial distribution for examining primary care visits based on preliminary analyses of the distribution of visits in these categories. The exponent of the coefficient represents the rate ratio of the utilization measures over time relative to the first six-month post-enrollment period.

The sample had too few Medicaid enrollees to independently examine the effects of Medicaid on
study outcomes. However, we conducted a sensitivity analysis, with participants who enrolled in the health system via Medicaid removed, to determine if this changed the results of service utilization analyses. All analyses were conducted using SAS v9.4. Significance level was set at 0.05 for all analyses.

Results

Sample characteristics
The sample included 880 PWH enrolled in the health care system in 2014 (Table 1). Participants were primarily male (92.6%) and ethnically diverse (48.3% non-white), with a mean age of 43.4 years (standard deviation = 10.9 years). Regarding type of health coverage and enrollment, 71.9% had no deductible and 15.9% were enrolled via the California Exchange; 26.6% had ADAP. There were no significant trends in the proportion of enrollees who obtained coverage via the Exchange or in deductible levels over time.

Table 1
Demographic Characteristics and Insurance Coverage of Newly Enrolled Health Plan Members with HIV.

| Demographic characteristics                  | N = 880 |
|-----------------------------------------------|---------|
| Gender                                        | n (%)   |
| Male                                          | 815 (92.6) |
| Female                                        | 65 (7.4)  |
| Age at enrollment                             |         |
| <26                                           | 45 (5.1)  |
| 26 to 35                                      | 192 (21.8) |
| 36 to 45                                      | 233 (26.5) |
| 46 to 55                                      | 288 (32.7) |
| 56 to 64                                      | 122 (13.9) |
| Race/Ethnicity                                |         |
| White                                         | 455 (51.7) |
| Black                                         | 146 (16.6) |
| Asian                                         | 70 (8.0)  |
| American Indian/Alaskan Native                | 3 (0.3)   |
| Native Hawaiian/Pacific Islander              | 9 (1.0)   |
| Hispanic                                      | 149 (16.9) |
| Unknown                                       | 48 (5.5)  |
| Deductible level                              |         |
| None                                          | 541 (71.9) |
| $1 to $999 (Low Deductible)                   | 77 (10.2)  |
| $1000 or more (High Deductible)               | 134 (17.8) |
| Enrollment mechanism                          |         |
| Exchange                                      | 140 (15.9) |
| Other mechanism (e.g., employer, Medicaid)    | 740 (85.1) |
| ADAP Benefit                                  | 213 (24.2) |

Notes: The sample included PWH newly enrolled in Kaiser Permanente Northern California between 1/1/2014 and 12/31/2014. Payer type included commercial (92.8%), Medicaid (6.6%), and other (0.5%). ADAP = AIDS Drug Assistance Program enrollment in 2014.

Longitudinal Trends In Services Use And Hiv Clinical Outcomes
Nearly all the sample (97.3%) had at least one primary care visit during the 36-month study period (not shown). Bivariate frequencies showed that the percentage of PWH with a primary care visit declined significantly (p < 0.001) from 91.8% in the first six months of enrollment to 74.0% by the last six-month period (Table 2a) as a percentage of those who were members during the respective six-month periods. About one-fifth (21.9%) of the sample had at least one psychiatry visit; the percentage of patients using psychiatry ranged from 9.2–6.6% by year three but no significant decreasing trend was identified. During the 36-month study period, 6.3% of individuals had a visit to a substance use clinic, and rates of use were stable over time. Over one-tenth (12.4%) of the sample had an inpatient stay during the 3-year study period. The percentage of people with an inpatient stay ranged from 3.8% in the first six months to 2.0% by the last six-month window though no significant decreasing trend was identified. A substantial percentage of PWH (41.1%) had at least one ED visit in 36 months; the rates ranged from 14.9% in the first six months to 12.1% in 18–24 months, and to 14.6% by year three. The trend was not statistically significant.

HIV clinical outcomes improved over time as measured by the increase in the proportion of individuals with HIV RNA control < 75 mL and improvement in CD4 counts (Table 2b). Most of the sample (95.8%) had at least one measure of CD4 count during the three years; 95.6% had at least one HIV RNA laboratory measure during this time. Among those who had at least one CD4 measure, mean CD4 count increased significantly (F-test p < 0.001) from 633.8 to 713.9 over three years. Among those who had an HIV RNA measure, at least 80% had HIV RNA levels < 75 copies/mL in every six-month period; there was an increase over three years, from 84.4% in the first 6-month period after enrollment to 93.1% by three years (p < 0.001).
Table 2
Unadjusted Post-ACA Trends in Health Services Utilization and HIV Clinical Outcomes over 36 Months Among Enrolled Members with HIV.

Table 2(a)

| Services Use | 0 - 6 months | 6 - 12 months | 12 - 18 months | 18 - 24 months | 24 - 30 months | 30 mc |
|--------------|--------------|---------------|----------------|----------------|----------------|-------|
| (% with Any Use) | | | | | | |
| Primary Care** | 91.8% | 78.4% | 77.0% | 74.0% | 74.8% | 74 |
| Psychiatry | 9.2% | 8.8% | 8.7% | 7.8% | 6.5% | 6 |
| Substance Use Treatment | 3.1% | 2.8% | 2.5% | 2.1% | 2.5% | 2 |
| Inpatient | 3.8% | 3.8% | 4.2% | 2.8% | 3.3% | 2 |
| Emergency | 14.9% | 13.0% | 13.9% | 12.1% | 12.7% | 14 |

Table 2(b)

| HIV Clinical Parameters | 0 - 6 months | 6 - 12 months | 12 - 18 months | 18 - 24 months | 24 - 30 months | 30 mc |
|-------------------------|--------------|---------------|----------------|----------------|----------------|-------|
| Mean CD4 Count** | 633.8 | 639.7 | 653.2 | 677.8 | 682.3 | 71 |
| (Std. Dev.) | (287.6) | (307.5) | (314.3) | (303.2) | (320.4) | (3) |
| HIV RNA level < 75 copies/mL(%)** | 84.4% | 91.0% | 91.1% | 93.7% | 93.3% | 93 |

Notes: Percentages are based on enrolled sample within each 6-month time period. ** p < .01. Significance levels for services use and HIV RNA level are based on the chi-squared statistic. Significance levels for mean CD4 count are based on the F-statistic.

Multivariate Analyses Of Service Utilization

Logistic regression models including demographic factors, enrollment through the Exchange, deductible level and ADAP did not show any longitudinal trends in dichotomous measures of services use (except for primary care) which suggested that the likelihood of hospitalization, ED use, psychiatry and substance use treatment services was stable over time (not shown). Those with high deductibles were less likely to use primary care (OR = 0.64, 95% CI = 0.49–0.83, p < 0.001) or psychiatric services (OR = 0.58, 95% CI = 0.36, 0.93, p = 0.02) compared to those with low or no
deductibles. Exchange enrollees were less likely to use psychiatric services (OR = 0.48, 95% CI: 0.27, 0.85, p = 0.01), (not shown).

We also examined the number of visits to primary care, psychiatry and substance use departments. There was a decreasing trend in frequency over 36 months (Table 3). The most consistent and significant decreases were in primary care, which declined by 42% (1- 0.58) in the six to twelve months post-enrollment period relative to the first six months after enrollment; this trend continued and by three years, participants had 53% fewer visits relative to 0-6 months post-enrollment. Those with high deductibles had 21% fewer primary care visits (RR = .79, 95% CI = 0.71-0.88, p < 0.001).

Table 3
Multivariate Analyses of Number of Primary Care, Psychiatry and Substance Use Disorder Treatment Visits Over 36 Months Among Newly Enrolled Members with HIV.

| Primary Care Visits | RR (95% CI) | P |
|---------------------|-------------|---|
| Time window (Reference=0 to 6 months) | | |
| 6-12 months | 0.58 (0.53 - 0.63) | <0.001 |
| 12-18 months | 0.52 (0.47 - 0.56) | <0.001 |
| 18-24 months | 0.47 (0.42 - 0.51) | <0.001 |
| 24-30 months | 0.47 (0.43 - 0.52) | <0.001 |
| 30-36 months | 0.47 (0.42 - 0.52) | <0.001 |
| Race (Reference=White) | 1.09 (0.98 - 1.22) | 0.10 |
| Gender (Reference=male) | 1.49 (1.23 - 1.82) | <0.001 |
| Age (at enrollment) | 1.01 (1.00 - 1.01) | <0.001 |
| Deductible level (reference=none) | | |
| Low deductible | 1.04 (0.90 - 1.20) | 0.56 |
| High deductible | 0.79 (0.71 - 0.88) | <0.001 |
| Exchange (Reference=not through Exchange) | 1.00 (0.90 - 1.12) | 0.95 |
| AIDS Drug Assistance Program (Reference=none) | 1.10 (0.98 - 1.23) | 0.11 |
| Psychiatry Visits | | |
| Time window (Reference=0 to 6 months) | | |
| 6-12 months | 1.16 (0.74 - 1.82) | 0.51 |
| 12-18 months | 0.77 (0.49 - 1.22) | 0.27 |
| 18-24 months | 0.83 (0.45 - 1.55) | 0.56 |
| 24-30 months | 0.82 (0.47 - 1.43) | 0.48 |
| 32 | | |
| 30-36 months | 0.61 (0.38 - 0.96) | 0.03 |
| Race (Reference=White) | 0.97 (0.50 - 1.90) | 0.93 |
| Substance Use Treatment Visits | RR (95% CI) | P  |
|-------------------------------|-------------|----|
| Time window                   |             |    |
| (Reference=0 to 6 months)     |             |    |
| 6-12 months                   | 0.87 (0.40 - 1.91) | 0.72 |
| 12-18 months                  | 0.89 (0.37 - 2.18) | 0.80 |
| 18-24 months                  | 0.43 (0.17 - 1.05) | 0.06 |
| 24-30 months                  | 0.26 (0.11 - 0.65) | 0.004 |
| 32                             |             |    |
| 30-36 months                  | 0.19 (0.07 - 0.53) | 0.002 |
| Race (Reference=White)        | 0.82 (0.29 - 2.30) | 0.71 |
| Gender (Reference=male)       | 2.41 (0.46 - 12.64) | 0.30 |
| Age (at enrollment)           | 0.99 (0.96 - 1.01) | 28  |
| Deductible level (reference=none) a |       |    |
| Low deductible                | 2.27 (0.80 - 6.49) | 0.12 |
| High deductible               | 1.32 (0.24 - 7.35) | 0.75 |
| Exchange (Reference=not through Exchange) b | 1.30 (0.40 - 4.16) | 0.66 |
| AIDS Drug Assistance Program (Reference=none) | 0.49 (0.12 - 2.10) | 0.34 |

Notes: RR=Rate ratio; CI= confidence interval. a Low deductible=$1 to $999; high deductible >= $1000 (comparison= no deductible). b California Insurance Exchange vs. other mechanisms.

Psychiatry visits increased in the first year and decreased gradually thereafter; by three years, individuals were using 39% fewer psychiatry visits (p = .03) relative to the period immediately after
enrollment. Individuals with high deductibles (RR = 0.51, 95% CI = 0.26–0.99, p = 0.05) were likely to have fewer psychiatry visits compared to those with no deductibles; individuals enrolled through the Exchange (RR = 0.38, 95% CI = 0.17–0.83, p = 0.02) had fewer visits compared to those enrolled through other mechanisms. Enrollment in ADAP was associated with greater use of psychiatry (RR = 2.22, 95% CI = 1.22–4.05, p = 0.01).

Visits to substance use treatment also declined, but the decreases were larger after 18 months, and by three years PWH had 81% fewer substance use treatment visits. Benefit-related factors (enrollment through the Exchange, deductible levels and ADAP) were not significantly associated with visits (Table 3).

**Multivariate Analyses of HIV Clinical Outcomes**

Mean CD4 counts showed a steady increase over time, with coefficients (relative to 0–6 months) increasing from 29.1 in the 6–12 months post-enrollment to 93.6 by 30–36 months (Table 4). All individuals were increasingly likely to have viral control (HIV RNA < 75 copies/mL) over time.

Approximately twice as many individuals (OR = 2.04, 1.46–2.85, p < .001) were likely to have HIV RNA < 75 copies/mL in the 6–12 twelve months post-enrollment period compared to the first six months after enrollment; they were three times as likely (OR = 3.28, 95% CI = 2.01–5.34, p < .001) to have HIV RNA < 75 copies/mL by 30–36 months post-enrollment. Enrollment through the Exchange and deductible level were not significantly associated with CD4 count or HIV RNA but enrollees in ADAP were more than twice as likely to have HIV RNA < 75 copies/mL compared to others (OR = 2.23, 95% CI = 1.35–3.68) p < 0.001). Non-white PWH were less likely to be virally suppressed, (OR = 0.47, 95% CI = 0.31–0.71, p < 0.001).
Table 4  
Multivariate Analyses of CD4 Counts and Viral Control Over 36 Months Among Newly Enrolled KPNC Members with HIV.

| CD4 Count | Coefficient (95% CI) | P    |
|-----------|----------------------|------|
| Time window (Reference = 0 to 6 months) | | |
| 6–12 months | 29.08 (13.70–44.45) | 0.00 |
| 12–18 months | 46.80 (29.82–63.78) | < 0.001 |
| 18–24 months | 63.16 (45.74–80.69) | < 0.001 |
| 24–30 months | 69.61 (50.07–89.15) | < 0.001 |
| 30–36 months | 93.61 (72.01–115.21) | < 0.001 |
| Race (Reference = White) | -77.44 (-119.26 - -35.63) | < 0.001 |
| Gender (Reference = Male) | 28.81 (-61.55–119.18) | 0.53 |
| Age (at enrollment) | -2.09 (-3.95 - -0.24) | 0.03 |
| Deductible level (reference = none) | | |
| Low deductible | -13.88 (-43.45–15.7) | 0.36 |
| High deductible | 13.07 (-15.26–41.40) | 0.37 |
| Exchange (Reference = Not through Exchange) | 14.33 (-12.26–41.23) | 0.30 |
| AIDS Drug Assistance Program (Reference = none) | 25.44 (-21.19–72.06) | 0.28 |

Sensitivity Analysis with Medicaid Enrollees Removed

The utilization models were repeated after excluding those with Medicaid, with a few minor changes noted: In analysis of predictors of number of primary care visits, the effect of ADAP enrollment became significant (RR = 1.16 (95% CI = 1.03,1.31, p = .01), rather than non-significant (p = .11, Table 3). In analysis of predictors of number of psychiatry visits, high deductible became non-significant (RR = 0.54, 95% CI = 0.26, 1.13, p = .10) rather than borderline significant (p = .05, Table 3). All other coefficients in all the other utilization models were substantively the same (i.e.,
significance or insignificance of the coefficients remained the same).

Discussion
The ACA remains an essential mechanism for increasing access to health insurance for PWH in the U.S, and it is important to examine its role in health service utilization and HIV clinical outcomes over time in combination with other factors that have an impact on PWH, including deductibles and ADAP. Overall, our study findings indicated that use of health care was highest immediately after enrollment; and that coverage through the California Exchange and deductible level had some impact on service utilization, although the effect varied by service. ADAP benefits were associated with access to psychiatry and better HIV viral control.

We found that most of the study sample (91.8%) had a primary care visit within six months of enrollment. Since primary care in this health system included HIV treatment, this is an encouraging indicator that KPNC staffing and services were adequate overall for PWH soon after implementation of the substantial health policy changes and enrollment increases associated with the ACA. Consistent with prior studies examining utilization [27, 28], we found that primary care utilization was highest immediately following enrollment and then decreased. Apart from deductibles, a factor contributing to having fewer primary care visits over time may be improvement in antiretroviral effectiveness [29, 30], which has led to a decrease in the recommended frequency of laboratory testing among individuals with long-term stable viral suppression.

We examined the effects of enrollment through the Exchange and deductible levels because these ACA features continue to be a major focus of policy in the U.S. Efforts were made on the part of some California health systems [6] and the Exchange itself [10] to educate new members (and potential members) on tiers of coverage and health care initiation processes. Although it is not known if other states made similar efforts, the Exchange in California represented a novel mechanism of coverage and entailed potential challenges both in determining how to choose coverage and sign up (pre-enrollment) and in understanding benefits and services (post-enrollment) [4]. Our findings that enrollment through the Exchange made no difference in accessing primary care or in HIV outcomes for newly enrolled PWH suggests that regardless of mechanism, new enrollees were able to access
core services and achieve viral suppression.

One recent study in California found that those with employer-based insurance had greater access to providers than those with either on-exchange and off-exchange individual private insurance plans or Medicaid [31]. Consistent with our psychiatry utilization findings, this study found worse access to primary care among those with private coverage purchased on exchanges compared to private coverage purchased individually [31]. Another study found that patients often felt overwhelmed by the array of choices offered on the exchanges and were confused by terminology and websites [32]. The reason for the effects of enrollment through the Exchange on psychiatry utilization in our sample could also be due to higher cost-sharing in Exchange plans (apart from deductibles) or to unexamined group differences such as financial constraints or fewer mental health problems among Exchange vs. non-exchange enrollees.

It is important to for patients and providers to understand how coverage policies affect services for PWH. One early study conducted in 2013 indicated that most PWH felt that they were not informed enough to make ACA-related decisions about their insurance [33]. HIV treatment provider knowledge regarding the ACA also is variable [34]. Our finding that higher deductibles did not impact HIV outcomes was a welcome result in light of the potential for higher deductibles to negatively impact care [35]. This may indicate that PWH were motivated to initiate primary care regardless of deductible level. ADAP financial support could also play a role in offsetting the effects of higher deductibles on access to care [36]. Prior work in the KPNC health care system found that HIV care coordinators make an active effort to “onboard” newly enrolled PWH, including ADAP enrollment [6], which could have had a positive impact on management of costs associated with deductibles as well as linkage to psychiatry. It is not known if other health systems made such efforts. However, similar to our findings, one prior study found that increased out-of-pocket spending on antiretroviral therapy associated with Medicare Part D enrollment did not have an impact on HIV viral suppression [36]. These results suggest that PWH who face higher deductible costs, at least in some health systems, have been able to manage these obligations without compromising viral suppression.

It is worth noting that we found worse HIV outcomes for non-White PWH, despite similar utilization of
primary care, mental health, and substance use treatment. Race/ethnic disparities in HIV care are a longstanding concern in the HIV treatment field. It was hoped that disparities would be at least partially mitigated post-ACA [4, 37], although recent data indicate that non-whites continue to have worse HIV care outcomes across multiple health care settings [38-40]. It is possible that factors associated with race/ethnicity and worse HIV outcomes but not measured in our study, such as health literacy [41] and variability in use of electronic provider communication tools [42, 43] could have contributed to these differences. The race/ethnic disparities in HIV clinical outcomes observed in our sample, in which overall insurance coverage was not a barrier to care, highlight the importance of addressing this ongoing challenge to health equity.

Study Strengths And Limitations
The study was conducted in a large integrated health system with access to data on type of insurance coverage, enrollment mechanisms, ADAP, use of health services and routine laboratory measures; and measured outcomes over three years following ACA implementation. However, limitations should be noted. The California Exchange continues to modify its coverage options [44, 45], and the effects of enrollment via the Exchange on outcomes of interest are likely to shift over time. Data on insurance coverage and viral control prior to KPNC enrollment were not available. Loss to follow up is also a limitation: although retention was high, HIV outcomes were based on PWH who remained in care and could be high compared to those who did not complete routine laboratory testing or left the health plan during study follow-up.

Although Medicaid expansion has benefitted PWH [46, 47], too few Medicaid beneficiaries were identified to examine separately. Yet repeating our analyses with Medicaid beneficiaries excluded, as a sensitivity analysis, resulted in few changes to the results. There is variability in the ways that patients can use ADAP in California (i.e., support for medication purchases as well as help in purchasing insurance and covering co-pays) [48], which we were not able to examine. However, we included ADAP status using prescription records as an indicator of whether study participants had received financial assistance through this program.

The impact of the ACA on HIV care may vary by state [49], limiting generalizability. The sample was
drawn from a single institution in California and participants had relatively high levels of viral control relative to PWH in other settings such as Ryan White clinics [40, 50]. However, economic barriers to service utilization for PWH with access to care are of concern in many health systems, including systems in other states and countries, and our study contributes to this important area of inquiry. In addition, conducting the study in single large integrated health care allowed us to examine ACA-related research questions without needing to control for variability across health care insurance and treatment providers.

Conclusions
This study examined factors associated with use of health care and HIV control among PWH following ACA implementation in a California health system. Outpatient utilization was highest immediately after enrollment and subsequently decreased. Enrollment through the Exchange and higher deductibles were negatively associated with psychiatric services, but did not appear to impact HIV outcomes, which improved over time and were associated with ADAP enrollment. Race/ethnic disparities in HIV clinical outcomes remain critical to address among PWH post-ACA, even in integrated health plans. It is essential that PWH maintain continuous access to health care in order to benefit fully from pharmacological advances in HIV treatment and to manage common medical and psychiatric comorbidities. As health care reform continues to develop, health care providers and policy leaders must consider potential effects on PWH.

Declarations
Availability of data and materials
The datasets generated and/or analyzed during the current study are not publicly available. Active partnerships between external researchers and the parent study team facilitates more productive collaborations that will effectively leverage the investment to develop the data as compared with generation of public use datasets. Upon request, de-identified data will be made available as study manuscripts are published. However, there remains the possibility of deductive disclosure of participants with unusual characteristics and disclosure of Kaiser Permanente proprietary information. Thus, researchers who seek access to individual level data will be required to sign a data sharing agreement. After the end of the project funding period, the cost of computer programmers preparing
de-identified datasets suitable for sharing will be borne by the party requesting the data.

Consent for Publication
Not applicable

Ethics approval and consent to participate
Study procedures were approved by the University of California San Francisco (UCSF) and KPNC Institutional Review Boards and included waivers of informed consent.

Competing Interests
The authors declare they have no competing interests.

Funding
This study was supported by the National Institute on Drug Abuse (R21/R33 DA035645) and the Tobacco-Related Disease Research Program (24XT-0008). Dr. Satre is also supported by a grant from the National Institute on Alcohol Abuse and Alcoholism (K24 AA025703). Dr. Williams is supported by a Career Development Award from VA Health Services Research & Development (CDA 12-276).

Authors’ Contributions
DDS and CIC conceived the study and obtained funding. SP designed the analysis plan and completed data analysis. All authors contributed to data interpretation as well as drafting and revising the manuscript. All authors read and approved the final manuscript.

Acknowledgements
We thank Agatha Hinman for assistance in preparing the manuscript.

References
1. Congress US. Patient Protection and Affordable Care Act, 42 U.S.C. § 18001. Public Law 111–148. 2010. . Accessed December 11, 2019.
2. Druss BG, Mauer BJ. Health care reform and care at the behavioral health–primary care interface. Psychiatr Serv. 2010;61(11):1087-92.
3. Buck JA. The looming expansion and transformation of public substance abuse treatment under the Affordable Care Act. Health Aff (Millwood). 2011;30(8):1402-10.
4. Lipira L, Williams EC, Hutcheson R, Katz AB. Evaluating the impact of the Affordable Care Act on HIV care, outcomes, prevention, and disparities: A critical research agenda. J Health Care Poor Underserved. 2017;28(4):1254-75.
5. Berry SA, Fleishman JA, Yehia BR, Cheever LW, Hauck H, Korthuis PT, et al. Healthcare coverage for HIV provider visits before and after implementation of the Affordable Care Act. Clin Infect Dis. 2016;63(3):387–95.

6. Satre DD, Altschuler A, Parthasarathy S, Silverberg MJ, Volberding P, Campbell CI. Implementation and operational research: Affordable Care Act implementation in a California health care system leads to growth in HIV-positive patient enrollment and changes in patient characteristics. J Acquir Immune Defic Syndr. 2016;73(5):e76-e82.

7. McManus KA, Rhodes A, Bailey S, Yerkes L, Engelhard CL, Ingersoll KS, et al. Affordable Care Act qualified health plan coverage: Association with improved HIV viral suppression for AIDS drug assistance program clients in a Medicaid nonexpansion state. Clin Infect Dis. 2016;63(3):396–403.

8. McManus KA, Rhodes A, Yerkes L, Engelhard CL, Ingersoll KS, Dillingham R. Year 2 of Affordable Care Act Qualified Health Plans (QHPs) in a Medicaid nonexpansion state: QHPs associated with viral suppression for Virginia AIDS Drug Assistance Program clients. Open Forum Infect Dis. 2018;5(12):ofy283.

9. Furl R, Watanabe-Galloway S, Lyden E, Swindells S. Determinants of facilitated health insurance enrollment for patients with HIV disease, and impact of insurance enrollment on targeted health outcomes. BMC Infect Dis. 2018;18(1):132.

10. Covered California. Information for individuals with HIV or AIDS. 2020. Accessed April 2, 2020.

11. Norris L Should you look outside the ACA’s exchanges? Obamacare Enrollment Guide 2019. Accessed April 2, 2020.

12. Abdus S, Selden TM, Keenan P. The financial burdens of high-deductible plans. Health Aff (Millwood). 2016;35(12):2297–301.

13. Agarwal R, Mazurenko O, Menachemi N. High-deductible health plans reduce health
care cost and utilization, including use of needed preventive services. Health Aff (Millwood). 2017;36(10):1762-8.

14. California Department of Public Health. Employer Based Health Insurance Premium Payment (EB-HIPP). Office of AIDS 2017. . Accessed April 2, 2020.

15. National Alliance of State & Territorial AIDS Directors. 2019 National RWHAP Part B and ADAP Monitoring Project annual report. 2019. . Accessed April 2, 2020.

16. Institute of Medicine Roundtable on Evidence-Based Medicine, Yong PL, Saunders RS, Olsen LA, editors. The Healthcare Imperative: Lowering Costs and Improving Outcomes: Workshop Series. Washington, DC: National Academies Press; 2010.

17. Shortell SM, McCurdy RK. Integrated health systems. Stud Health Technol Inform. 2010;153:369 – 82.

18. Covered California. Health insurance through Covered California. 2020. . Accessed April 2, 2020.

19. Andersen RM. Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav. 1995;36(1):1-10.

20. Weisner C, Matzger H, Tam T, Schmidt L. Who goes to alcohol and drug treatment? Understanding utilization within the context of insurance. J Stud Alcohol Drugs. 2002;63(6):673 – 82.

21. Dhingra SS, Zack M, Strine T, Pearson WS, Balluz L. Determining prevalence and correlates of psychiatric treatment with Andersen's behavioral model of health services use. Psychiatr Serv. 2010;61(5):524-8.

22. DeLorenze GN, Satre DD, Quesenberry CP, Tsai AL, Weisner CM. Mortality after diagnosis of psychiatric disorders and co-occurring substance use disorders among HIV-infected patients. AIDS Patient Care STDS. 2010;24(11):705 – 12.

23. Campbell CI, Parthasarathy S, Altschuler A, Young-Wolff KC, Satre DD. Characteristics
of patients with substance use disorder before and after the Affordable Care Act. Drug Alcohol Depend. 2018;193:124 – 30.

24. Satre DD, Parthasarathy S, Altschuler A, Silverberg MJ, Storholm E, Campbell CI. Demographic, insurance, and health characteristics of newly enrolled HIV patients after implementation of the Affordable Care Act in California. Am J Public Health. 2016;106(7):1211-3.

25. Chao C, Tang B, Hurley L, Silverberg MJ, Towner W, Preciado M, et al. Risk factors for short-term virologic outcomes among HIV-infected patients undergoing regimen switch of combination antiretroviral therapy. AIDS Res Hum Retroviruses. 2012;28(12):1630-6.

26. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73(1):13–22.

27. Hofer AN, Abraham JM, Moscovice I. Expansion of coverage under the Patient Protection and Affordable Care Act and primary care utilization. Milbank Q. 2011;89(1):69–89.

28. Sommers BD, Blendon RJ, Orav EJ, Epstein AM. Changes in utilization and health among low-income adults after Medicaid expansion or expanded private insurance. JAMA Intern Med. 2016;176(10):1501-9.

29. Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA, et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;58(1):1-10.

30. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of Health and Human Services 2019. . Accessed April 2, 2020.
31. Alcala HE, Roby DH, Grande DT, McKenna RM, Ortega AN. Insurance type and access to health care providers and appointments under the Affordable Care Act. Med Care. 2018;56(2):186 – 92.

32. Mulligan J. The problem of choice: From the voluntary way to Affordable Care Act health insurance exchanges. Soc Sci Med. 2017;181:34-42.

33. Rozin I, Sayles H, Anderson MJ, Furl R, Stimpson JP, Swindells S, et al. HIV-infected patient knowledge, attitudes, and beliefs regarding the Affordable Care Act. AIDS Res Hum Retroviruses. 2015;31(6):581-6.

34. McManus KA, McManus K, Dillingham R. National survey of United States human immunodeficiency virus medical providers' knowledge and attitudes about the Affordable Care Act. Clin Infect Dis. 2018;67(9):1403-10.

35. Reed M, Fung V, Price M, Brand R, Benedetti N, Derose SF, et al. High-deductible health insurance plans: Efforts to sharpen a blunt instrument. Health Aff (Millwood). 2009;28(4):1145-54.

36. Belenky N, Pence BW, Cole SR, Dusetzina SB, Edmonds A, Oberlander J, et al. Associations between Medicare Part D and out-of-pocket spending, HIV viral load, adherence, and ADAP use in dual eligibles with HIV. Med Care. 2018;56(1):47–53.

37. Ginossar T, Oetzel J, Van Meter L, Gans AA, Gallant JE. The Ryan White HIV/AIDS Program after the Patient Protection and Affordable Care Act full implementation: a critical review of predictions, evidence, and future directions. Top Antivir Med. 2019;27(3):91–100.

38. Crepaz N, Dong X, Hess KL, Bosh K. Brief report: Racial and ethnic disparities in sustained viral suppression and transmission risk potential among persons aged 13–29 years living with diagnosed HIV infection, United States, 2016. J Acquir Immune Defic Syndr. 2020;83(4):334-9.
39. Anderson AN, Higgins CM, Haardorfer R, Holstad MM, Nguyen MLT, Waldrop-Valverde D. Disparities in retention in care among adults living with HIV/AIDS: A systematic review. AIDS Behav. 2020;24(4):985 – 97.

40. Sheehan DM, Dawit R, Gbadamosi SO, Fennie KP, Li T, Gebrezgi M, et al. Sustained HIV viral suppression among men who have sex with men in the Miami-Dade County Ryan White Program: the effect of demographic, psychosocial, provider and neighborhood factors. BMC Public Health. 2020;20(1):326.

41. Waldrop-Valverde D, Murden RJ, Guo Y, Holstad M, Ownby RL. Racial disparities in HIV antiretroviral medication management are mediated by health literacy. Health Lit Res Pract. 2018;2(4):e205-e13.

42. Javier SJ, Troszak LK, Shimada SL, McInnes DK, Ohl ME, Avoundjian T, et al. Racial and ethnic disparities in use of a personal health record by veterans living with HIV. J Am Med Inform Assoc. 2019;26(8-9):696–702.

43. Marhefka SL, Lockhart E, Turner D, Wang W, Dolcini MM, Baldwin JA, et al. Social determinants of potential eHealth engagement among People Living with HIV receiving Ryan White Case Management: Health equity implications from Project TECH. AIDS Behav. 2019.

44. Robinson J, Price A, Goldman Z. The redesign of consumer cost sharing for specialty drugs at the California Health Insurance Exchange. Am J Manag Care. 2016;22(4 Suppl):s87-91.

45. McMenamin SB, Shimkhada R, Hiller SP, Corbett G, Ponce N. Addressing discriminatory benefit design for people living with HIV: a California case study. AIDS Care. 2017;29(12):1594-7.

46. Kates J, Dawson L. Insurance coverage changes for people with HIV under the ACA. Kaiser Family Foundation 2019. . Accessed April 2, 2020.
47. Arnold EA, Fuller S, Kirby V, Steward WT. The impact of Medicaid expansion on people living with HIV and seeking behavioral health services. Health Aff (Millwood). 2018;37(9):1450-6.

48. National Alliance of State &
Monitoring Project

National Alliance of State &. Territorial AIDS, Directors, Bowes A, Lefert A, Pund B. National ADAP. Monitoring Project. 2015. . Accessed April 2, 2020.

49. Hood JE, Buskin SE, Anderson BJ, Gagner A, Kienzle J, Maggio D, et al. A cross-jurisdictional evaluation of insurance coverage among HIV care patients following the Affordable Care Act. AIDS Care. 2017;29(4):511-5.

50. Klein PW, Geiger T, Chavis NS, Cohen SM, Ofori AB, Umali KT, et al. The Health Resources and Services Administration's Ryan White HIV/AIDS Program in rural areas of the United States: Geographic distribution, provider characteristics, and clinical outcomes. PLoS One. 2020;15(3):e0230121.